REVIEW

LSD1, a double-edged sword, confers dynamic chromatin regulation but commonly promotes aberrant cell growth

[version 1; peer review: 2 approved]

Meghan M Kozub¹, Ryan M Carr², Gwen L Lombark³,
Martin E Fernandez-Zapico ²

¹Genomics Laboratories, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA

²Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, USA

³Division of Research, Department of Surgery, Medical College of Wisconsin, Milwaukee, USA

V1 First published: 16 Nov 2017, 6(F1000 Faculty Rev):2016
<https://doi.org/10.12688/f1000research.12169.1>

Latest published: 16 Nov 2017, 6(F1000 Faculty Rev):2016
<https://doi.org/10.12688/f1000research.12169.1>

Abstract

Histone-modifying enzymes play a critical role in chromatin remodeling and are essential for influencing several genome processes such as gene expression and DNA repair, replication, and recombination. The discovery of lysine-specific demethylase 1 (LSD1), the first identified histone demethylase, dramatically revolutionized research in the field of epigenetics. LSD1 plays a pivotal role in a wide range of biological operations, including development, cellular differentiation, embryonic pluripotency, and disease (for example, cancer). This mini-review focuses on the role of LSD1 in chromatin regulatory complexes, its involvement in epigenetic changes throughout development, and its importance in physiological and pathological processes.

Keywords

LSD1, KDM1a, histone demethylation, epigenetics, cancer

Open Peer Review

Approval Status

	1	2
version 1
16 Nov 2017		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Barbara Majello**, University of Naples
Federico II, Naples, Italy

2. **Philip Cole**, Johns Hopkins University School
of Medicine, Baltimore, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Martin E Fernandez-Zapico (fernandezzapico.martin@mayo.edu)

Author roles: **Kozub MM:** Conceptualization, Writing – Original Draft Preparation; **Carr RM:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Lomberg GL:** Conceptualization, Writing – Original Draft Preparation; **Fernandez-Zapico ME:** Conceptualization, Resources, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by National Institutes of Health/National Cancer Institute CA136526, Mayo Clinic Pancreatic SPORE P50 CA102701, and Mayo Clinic Center for Cell Signaling in Gastroenterology P30 DK84567 to MEF-Z.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Kozub MM *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Kozub MM, Carr RM, Lomberg GL and Fernandez-Zapico ME. **LSD1, a double-edged sword, confers dynamic chromatin regulation but commonly promotes aberrant cell growth [version 1; peer review: 2 approved]** F1000Research 2017, 6 (F1000 Faculty Rev):2016 <https://doi.org/10.12688/f1000research.12169.1>

First published: 16 Nov 2017, 6(F1000 Faculty Rev):2016 <https://doi.org/10.12688/f1000research.12169.1>

Introduction

Within the nuclei of all eukaryotic cells, DNA is highly compacted via interactions with histones and numerous other proteins to form chromatin. Histones are involved with supercoiling of DNA and are subjected to post-translation modifications (PTMs)¹. Diverse covalent modifications to histones control the structure and dynamics of chromatin and regulate access to DNA, ultimately altering gene expression. Multiple biochemical moieties can be covalently added to specific amino acids on the N-terminus of the histone, or “histone tail”^{1,2}. The sequence of histone tail modifications, or “histone code”, influences transcription and other processes, including DNA repair, replication, and recombination³.

Histone PTMs were historically thought to be irreversible until the discovery of enzymes catalyzing the addition and removal of methyl groups to lysine and arginine residues on histone tails⁴. Two evolutionarily conserved families of histone demethylases that recognize H3K4me as a substrate have been identified: lysine-specific demethylases (LSDs) and Jumonji C demethylases (JMJs)^{5–7}. LSD enzymes demethylate mono- and di-methyl groups of lysine residues and some non-histone targets. JMJs belong to the dioxygenase superfamily involved in deoxygenation reactions dependent on ferrous iron and α -ketoglutarate allowing demethylation of trimethylated lysine residues^{6,7}. Lysine-specific histone demethylase I (LSD1) was first described in 2004, inspiring the hypothesis that histone modification is a highly dynamic process⁸.

This review focuses on LSD1 (also known as KDM1a) and its role in various physiological and pathological processes. LSD1 acts on histone H3 as a transcription co-repressor through demethylation of lysine 4 (H3K4) or as a transcription co-activator through demethylation of lysine 9 (H3K9)^{9–11}. The enzyme is essential in the control of wide-ranging biological processes, including cell proliferation¹², chromosome segregation¹³, hematopoiesis¹⁴, spermatogenesis¹⁵, adipogenesis¹⁶, stem cell pluripotency¹⁷, and embryonic development¹⁸. LSD1 can act as an oncogene, and its overexpression promotes cancer cell proliferation, migration, and invasion^{10,11}.

LSD1 complex with regulatory proteins to facilitate histone demethylation

LSD1 consists of three structural domains: N-terminal SWIRM domain, C-terminal flavin adenine dinucleotide (FAD)-binding amine oxidase domain, and the tower domain. The SWIRM domain consists of proteins Swi3, Rsc8, and Moira. Through hydrophobic interactions, the FAD domain closely associated with SWIRM, forming a spherical core. Extending from the core is the tower domain forming an elongated helix-turn-helix motif.

Frequently, LSD1 is found to be associated with a transcriptional co-repressor protein (CoREST) and histone deacetylase (HDAC) 1/2 to form a complex. Interaction with CoREST is necessary for LSD1 H3K4 demethylation^{19–22}. Association of the FAD domain with CoREST-histone ternary complex results in conformational change, permitting association with the N-terminal H3 tail^{23,24}. With H3K4 in close proximity to the FAD domain, oxidative demethylation results in increased affinity for LSD1^{23,25–27}. LSD1 requires the first 20 N-terminal amino acids of the histone tail for substrate

recognition and interaction^{28,29}. The specific amino-acid sequence allows LSD1 to sense the epigenetic messages encoded within histone tail and efficiently carry out demethylation. The presence of other epigenetic marks on H3 has the potential to affect the enzymatic activity of LSD1, suggesting a regulatory role for the H3 tail bereft of all other epigenetic modifications upon LSD1 activity^{29,30}.

Within the aforementioned complex, LSD1 demethylates mono- and di-methylated H3K4^{7,25,30,31}. Earlier studies identified REST as a long-term repressor of neuronal genes in non-neuronal cells^{19,32–34}. This was determined to be mediated through the recruitment of the LSD1-CoREST-HDAC complex, thus allowing lysine deacetylation of H3 and H4 in addition to demethylation of H3K4³⁵. In other investigations, RNA interference (RNAi)-mediated knockdown of LSD1 resulted in H3K4 methylation mark recurrence in proximity to REST target promoters, confirming this regulatory function³⁰. While methylation of H3K4 activates transcription, demethylation by LSD1 confers transcriptional repression³². LSD1 also serves as a transcriptional activator. For example, androgen receptor (AR) activation of its target genes is dependent upon LSD1-mediated H3K9 demethylation²¹. Following hormone treatment, AR and LSD1 co-localize to promoters, resulting in H3K9 demethylation without changing H3K4 methylation status⁹. As expected, LSD1 knockdown resulted in reduced activation of AR-responsive promoters^{7,35}. Taken together, the above findings showed the potential of LSD1 as a transcriptional repressor or activator through dynamic and selective H3K4 demethylation and H3K9 demethylation, respectively (Figure 1).

LSD1 contributes to broad, dynamic gene regulation through histone demethylation

Under physiological conditions, LSD1 has been found to have several functions ranging from regulation of hormone receptor-mediated transcription, appropriate hematopoietic stem cell differentiation, and cell cycle control. Estrogen receptor (ER)-mediated transcription is driven by LSD1-mediated H3K9 demethylation at both the gene promoter and an upstream enhancer site. ER then takes part in bending chromatin to interact with RNA polymerase to promote transcription. LSD1 co-localizes to this DNA loop, and the process of demethylation results in formation of hydrogen peroxide, inducing local oxidative DNA damage, recruiting 8-oxoguanine-DNA glycosylase 1 and topoisomerase II β . These enzymes induce DNA conformational changes necessary for efficient promotion of gene expression^{36,37}. Thus, LSD1 plays an important role in hormone receptor-mediated gene expression via histone demethylation and through DNA damage-induced chromatin remodeling.

In addition to driving hormone receptor-mediated gene expression, LSD1 plays a critical role in hematopoiesis. LSD1 is dynamically involved in hematopoietic differentiation through cooperation with growth factor-independent (GFI) proteins. GFI proteins promote expression of lineage-specific genes, and LSD1 specifically interacts with GFI1B binding sites. In mouse models, RNAi depletion of LSD1 impairs both erythrocyte and megakaryocyte differentiation but activated spontaneous granulocyte differentiation. Therefore, actions of LSD1 may be lineage-specific³⁸. However, alternative

Figure 1. LSD1, through histone 3 demethylation, has dual functions as both a transcriptional activator and repressor. As an illustration of this, LSD1 (lysine-specific demethylase 1) can be associated with activated estrogen receptors (ERs) or androgen receptors (ARs) and promote demethylation at lysine 9 (K9) of the histone tail. This confers opening of heterochromatin, promoting transcriptional activation. Alternatively, LSD1 can complex with CoREST and histone deacetylase 1/2 (HDAC1/2). This association confers more specificity for methylated lysine 4 (K4), resulting in its demethylation. This promotes heterochromatin formation and transcriptional repression.

models have revealed competing findings that LSD1 is necessary for terminal differentiation of erythroid, megakaryocytic, and granulocytic lineages^{38–40}. Although its specific role is not fully characterized, LSD1 was found to regulate promoters and enhancers of genes associated with hematopoietic stem cells and was critical for terminal differentiation of mature hematopoietic cells as LSD1 knockout resulted in severe pancytopenia⁴¹.

Finally, LSD1 biological functions are associated with the regulation of the methylation status of non-histone proteins. Studies demonstrate the relationship between retinoblastoma gene (*RB1*) and LSD1 in cell cycle control. Overexpression of *RB1*, the first identified tumor suppressor, causes cells to undergo arrest in the G₁ phase of the cell cycle, and, as expected, abrogation of *RB1* accelerates G₁ transition^{42,43}. Phosphorylation is a key mechanism by which *RB1* is regulated. Dephosphorylation is mediated by myosin phosphatase, which promotes cell cycle arrest⁴⁴. Interestingly, myosin phosphatase target subunit 1 (MYPT1) was identified as a novel substrate of LSD1. Methylation of MYPT1 is mediated by LSD1, preventing dephosphorylation of *RB1* and ultimately promoting cell cycle progression¹². Given these diverse functions, one can

see how altered LSD1 activity could contribute significantly to normal homeostasis and pathology such as malignancy.

Aberrant LSD1 activity suppresses cell cycle regulators and promotes tumor growth

Given the aforementioned role of LSD1 in cell cycle regulation, one may hypothesize that it could serve as an oncogene in the context of malignant transformation. LSD1 was first found to be overexpressed in neuroblastoma, correlating with poor differentiation⁴⁵. Overexpression of LSD1 has been documented in many solid tumors and is correlated with aggressive clinicopathological features and poor patient outcomes^{11,46–49}. Both *in vitro* and *in vivo* models have demonstrated overexpression of LSD1 correlating with significant chromatin modifications and malignant transformation^{50,51}. Both pharmacological inhibition and genetic depletion of LSD1 have been shown to inhibit cancer cell proliferation, differentiation, invasion, and metastasis in animal models^{7,40,52}. Thus, LSD1 has been confirmed to be an important oncogenic driver, a potential biomarker indicative of poor prognosis, and a potential therapeutic target. There are several forms of malignancy that have been shown to have aberrant LSD1 activity.

First, LSD1 is critical in the process of terminal differentiation in hematopoiesis, and abnormal LSD1 activity is correlated with a variety of myeloproliferative disorders^{11,50,51,53}. Many studies propose LSD1 as a prospective treatment target for acute myeloid leukemia (AML). AML is a heterogeneous hematopoietic malignancy characterized by the accumulation of incompletely differentiated progenitor cells (blasts) in the bone marrow, causing suppression of normal hematopoiesis⁴¹. LSD1 is a required constituent of a mixed-lineage leukemia (MLL) super complex associated with active transcription sites⁵⁴. Abrogation of LSD1 results in heightened rates of apoptosis and impaired leukemogenicity in an MLL-AF9 mouse model⁵⁵. In acute promyelocytic leukemia, all-*trans* retinoic acid can induce differentiation of leukemic cells whereas AML is not responsive. However, inhibition of LSD1 activity in AML models results in increased H3K4me2 at myeloid differentiation-associated genes, resulting in increased responsiveness to all-*trans* retinoic acid⁴⁰. These data support the importance of LSD1-mediated alteration of the leukemic epigenome in pathogenesis and demonstrate how the enzyme could serve as a therapeutic target in AML.

LSD1 is also dysregulated in solid tumors, including colorectal carcinoma. Increased activity in colon cancer is associated with increased metastatic potential⁵⁶. Higher expression of LSD1 and low expression of CDH-1 (E-cadherin) in colorectal cancer were associated with higher tumor-node-metastasis staging and thus poorer prognosis⁵⁷. Knockdown of LSD1 results in CDH-1 upregulation and confers reduced invasiveness. LSD1 regulates the *CDH-1* promoter and demethylation of H3K4me2 causes downregulation of CDH-1 expression⁵⁸.

Squamous cell carcinoma (SCC) is also associated with elevated LSD1 activity. The most common genetic aberration in SCC of the lung, esophagus, and oral cavity is amplification of *Sox2*^{59–61}. *Sox2* encodes a transcription factor important in embryonic stem cells with the ability to reprogram somatic cells into induced pluripotent stem cells. Elevated LSD1 levels are associated with amplified *Sox2* expression in lung cancer. Cells from these patients are particularly sensitive to the LSD1 inhibitor, CBB1007, whereas *Sox2*-negative cells are not⁶². Subsequent chromatin immunoprecipitation (ChIP) sequencing revealed that LSD1 binds to the *Sox2* gene and is enriched in the transcriptional regulator region, a known distant enhancer for *Sox2* expression in breast cancer. LSD1 inhibition revealed that its activity is required for *Sox2* expression. Inactivation results in increased global H3K9me1/me2 and H3K27me3 with formation of bivalent chromatin domains within the regulatory regions of *Sox2* and cell cycle regulatory genes, leading to suppression of gene expression⁶³.

ER-negative breast cancer is a subtype of the common malignancy with relatively more rapid growth, loss of differentiation, and increased propensity for metastasis. Interestingly, LSD1 tends to be highly expressed in this form of breast cancer⁶⁴. LSD1 and HDAC closely interact and control the growth of breast cancer through aberrant gene silencing⁶⁵.

Upregulation of LSD1 promotes epithelial-to-mesenchymal transition

Aberrant LSD1 activity is extensively characterized in multiple cancers, but the mechanism by which it promotes cancer

progression extends beyond suppression of cell cycle regulators. For example, through PTM of a notable non-histone protein, p53, LSD1 represses apoptosis. This is achieved through demethylation of K370me2. Whereas methylation at this site promotes association of p53 with co-activator 53BP1, LSD1 inhibits this interaction⁶⁶. A more thoroughly studied role of LSD1 is in the epithelial-to-mesenchymal transition, a critical process in cancer progression. Snail and Slug are key molecular mediators of epithelial-to-mesenchymal transition through direct repression of epithelial markers such as CDH-1. This is achieved through the SNAG domain of Snail, structurally resembling the histone H3 tail, recruiting LSD1 to epithelial gene promoters with formation of the Snail-LSD1-CoREST complex with subsequent demethylation of H3K4me2^{67,68}. In the specific case of neuroblastoma, MYCN has been correlated with poor prognosis. This is related to the co-localization of LSD1 and MYCN at the promoter of a key suppressor of metastasis, N-Myc downstream-regulated gene 1 (NDRG1), inhibiting its expression. Thus, elevated LSD1 is associated with lower NDRG1 expression and poor prognosis⁶⁹. Inhibition of enzymatic activity or abrogation of the SNAG-LSD1 interaction suppresses mesenchymal markers, decreasing cancer invasiveness^{70,71}. Promoting transition to a mesenchymal phenotype is opposed by acetylation of LSD1 by males absent on the first (MOF). In fact, MOF expression correlates with favorable prognosis in cancer⁷².

In summary, there is an abundance of evidence for a role of LSD1 in the pathogenicity of a wide array of malignancies. Cancer is the consequence of complex and heterogeneous genetic alterations, and aberrant LSD1 activity can contribute to a malignant phenotype through extensive modifications of the epigenome. Therefore, therapeutic targeting of the demethylase may prove an effective strategy in reversing or attenuating more aggressive malignant phenotypes in many cancers.

Conclusions

This review has briefly summarized the current knowledge and research of LSD1, its expression patterns, recruitment mechanisms, chromatin remodeling, biochemical functions, molecular structure, and role in cancer. In the past several years, studies have elucidated the role that histone lysine demethylases play in epigenetic regulation. LSD1 was the first histone demethylase identified and catalyzes the oxidation of methylated H3K4 through an amine oxidation reaction. Furthermore, LSD1 can act on non-histone proteins. While LSD1 is critical in conferring the dynamic nature of epigenetic regulation through histone modification, imbalance in histone modification with excessive LSD1 activity is significantly associated with increased cellular growth and suppression of cell cycle regulatory proteins in a broad array of tissues. Thus, LSD1 represents a critical oncogene and potential therapeutic target. More is to be elucidated regarding the function of LSD1. Interestingly, Wang *et al.* reported that LSD1 inhibits the invasion of breast cancer cells *in vitro* but conversely suppresses breast cancer metastatic potential *in vivo*⁷³. These data suggest not only that LSD1 is multifunctional but also that its functions may be highly context-dependent. More extensive studies into the effects of these contexts on LSD1 function will be important to fully understand its role in cancer. A significant amount of research has been devoted to the development of a wide range of epigenetic therapies. Numerous questions still must be answered regarding

LSD1 if effective therapeutic strategies are to be developed. For example, what are the functions and interactions of other LSD1 domains, or does LSD interact with methyltransferases, and how are these relationships regulated? In regard to the development of further therapies, emphasis should be placed on the development of highly specific drugs for demethylase subtypes to better direct the desired epigenetic effect of the drug. This would help specifically discern enzyme subtype mechanism. Despite these challenges, LSD1 is clearly important in normal cellular functions and malignancy.

Competing interests

The authors declare that they have no competing interests.

Grant information

This work was supported by National Institutes of Health/National Cancer Institute CA136526, Mayo Clinic Pancreatic SPORE P50 CA102701, and Mayo Clinic Center for Cell Signaling in Gastroenterology P30 DK84567 to MEF-Z.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments

We would like to thank Emily Porcher for her secretarial assistance. We would like to acknowledge the contributions of the authors of the excellent research studies and comprehensive reviews that were cited herein. We apologize to any authors whose work we omitted because of space limitations.

References

- Jenuwein T, Allis CD: **Translating the histone code.** *Science*. 2001; **293**(5532): 1074–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Bannister AJ, Kouzarides T: **Regulation of chromatin by histone modifications.** *Cell Res*. 2011; **21**(3): 381–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kouzarides T: **Chromatin modifications and their function.** *Cell*. 2007; **128**(4): 693–705.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pedersen MT, Helin K: **Histone demethylases in development and disease.** *Trends Cell Biol*. 2010; **20**(11): 662–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Klose RJ, Kallin EM, Zhang Y: **JmJC-domain-containing proteins and histone demethylation.** *Nat Rev Genet*. 2006; **7**(9): 715–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chen X, Hu Y, Zhou DX: **Epigenetic gene regulation by plant Jumonji group of histone demethylase.** *Biochim Biophys Acta*. 2011; **1809**(8): 421–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Shi Y, Lan F, Matson C, *et al.*: **Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.** *Cell*. 2004; **119**(7): 941–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- "KDM1A Lysine Demethylase 1A [*Homo Sapiens* (human)]". National Center for Biotechnology Information. U.S. National Library of Medicine, n.d. Web. 29 June 2016.
- Metzger E, Wissmann M, Yin N, *et al.*: **LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.** *Nature*. 2005; **437**(7057): 436–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Scoumanne A, Chen X: **The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners.** *J Biol Chem*. 2007; **282**(21): 15471–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hayami S, Kelly JD, Cho HS, *et al.*: **Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers.** *Int J Cancer*. 2011; **128**(3): 574–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Cho HS, Suzuki T, Dohmae N, *et al.*: **Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells.** *Cancer Res*. 2011; **71**(3): 655–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lv S, Bu W, Jiao H, *et al.*: **LSD1 is required for chromosome segregation during mitosis.** *Eur J Cell Biol*. 2010; **89**(7): 557–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Li Y, Deng C, Hu X, *et al.*: **Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis.** *Oncogene*. 2012; **31**(48): 5007–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Godmann M, Auger V, Ferraroni-Aguar V, *et al.*: **Dynamic regulation of histone H3 methylation at lysine 4 in mammalian spermatogenesis.** *Biol Reprod*. 2007; **77**(5): 754–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Musiri MM, Carmona MC, Hanzu FA, *et al.*: **Histone demethylase LSD1 regulates adipogenesis.** *J Biol Chem*. 2010; **285**(39): 30034–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zhou H, Li W, Zhu S, *et al.*: **Conversion of mouse epiblast stem cells to an earlier pluripotency state by small molecules.** *J Biol Chem*. 2010; **285**(39): 29676–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Foster CT, Dovey OM, Lezina L, *et al.*: **Lysine-specific demethylase 1 regulates the embryonic transcriptome and CoREST stability.** *Mol Cell Biol*. 2010; **30**(20): 4851–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ballas N, Battaglioli E, Atouf F, *et al.*: **Regulation of neuronal traits by a novel transcriptional complex.** *Neuron*. 2001; **31**(3): 353–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Shi Y, Sawada J, Sui G, *et al.*: **Coordinated histone modifications mediated by a CtBP co-repressor complex.** *Nature*. 2003; **422**(6933): 735–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Humphrey GW, Wang Y, Russanova VR, *et al.*: **Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/ kiaa0071 and Mta-L1.** *J Biol Chem*. 2001; **276**(9): 6817–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
- You A, Tong JK, Grozinger CM, *et al.*: **CoREST is an integral component of the CoREST-human histone deacetylase complex.** *Proc Natl Acad Sci U S A*. 2001; **98**(4): 1454–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Fomeris F, Binda C, Adamo A, *et al.*: **Structural basis of LSD1-CoREST selectivity in histone H3 recognition.** *J Biol Chem*. 2007; **282**(28): 20070–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Yang M, Culhane JC, Szwedczuk LM, *et al.*: **Structural basis of histone demethylation by LSD1 revealed by suicide inactivation.** *Nat Struct Mol Biol*. 2007; **14**(6): 535–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Yang M, Gocke CB, Luo X, *et al.*: **Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1 histone demethylase.** *Mol Cell*. 2006; **23**(3): 377–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Stavropoulos P, Blobel G, Hoelz A: **Crystal structure and mechanism of human lysine-specific demethylase-1.** *Nat Struct Mol Biol*. 2006; **13**(7): 626–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Chen Y, Yang Y, Wang F, *et al.*: **Crystal structure of human histone lysine-specific demethylase 1 (LSD1).** *Proc Natl Acad Sci U S A*. 2006; **103**(38): 13956–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Fomeris F, Binda C, Vanoni MA, *et al.*: **Human histone demethylase LSD1 reads the histone code.** *J Biol Chem*. 2005; **280**(50): 41360–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fomeris F, Binda C, Dall'Aglio A, *et al.*: **A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1.** *J Biol Chem*. 2006; **281**(46): 35289–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Shi YJ, Matson C, Lan F, *et al.*: **Regulation of LSD1 histone demethylase activity by its associated factors.** *Mol Cell*. 2005; **19**(6): 857–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Lee MG, Wynder C, Cooch N, *et al.*: **An essential role for CoREST in**

- nucleosomal histone 3 lysine 4 demethylation. *Nature*. 2005; 437(7057): 432–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. **F** Bernstein BE, Kamal M, Lindblad-Toh K, *et al.*: Genomic maps and comparative analysis of histone modifications in human and mouse. *Cell*. 2005; 120(2): 169–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 33. **F** Ballas N, Grunseich C, Lu DD, *et al.*: REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. *Cell*. 2005; 121(4): 645–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 34. Ooi L, Wood IC: Chromatin crosstalk in development and disease: lessons from REST. *Nat Rev Genet*. 2007; 8(7): 544–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Forneris F, Binda C, Vanoni MA, *et al.*: Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. *FEBS Lett*. 2005; 579(10): 2203–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. **F** Perillo B, Ombrà MN, Bertoni A, *et al.*: DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. *Science*. 2008; 319(5860): 202–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 37. **F** Hu Q, Kwon Y, Nunez E, *et al.*: Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. *Proc Natl Acad Sci U S A*. 2008; 105(49): 19199–204.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 38. Adamo A, Sesé B, Boue S, *et al.*: LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. *Nat Cell Biol*. 2011; 13(6): 652–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Lokken AA, Zeleznik-Le NJ: Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. *Cancer Cell*. 2012; 21(4): 451–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. **F** Schenk T, Chen WC, Göllner S, *et al.*: Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. *Nat Med*. 2012; 18(4): 605–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 41. **F** Kerenyi MA, Shao Z, Hsu YJ, *et al.*: Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. *eLife*. 2013; 2: e00633.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 42. Lee WH, Bookstein R, Hong F, *et al.*: Human retinoblastoma susceptibility gene: cloning, identification, and sequence. *Science*. 1987; 235(4794): 1394–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Goodrich DW, Wang NP, Qian YW, *et al.*: The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. *Cell*. 1991; 67(2): 293–302.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Classon M, Harlow E: The retinoblastoma tumour suppressor in development and cancer. *Nat Rev Cancer*. 2002; 2(12): 910–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Schulte JH, Lim S, Schramm A, *et al.*: Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. *Cancer Res*. 2009; 69(5): 2065–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. **F** Amente S, Lania L, Majello BL: The histone LSD1 demethylase in stemness and cancer transcription programs. *Biochim Biophys Acta*. 2013; 1829(10): 981–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 47. Magerl C, Ellinger J, Braunschweig T, *et al.*: H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. *Hum Pathol*. 2010; 41(2): 181–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Lim S, Janzer A, Becker A, *et al.*: Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. *Carcinogenesis*. 2010; 31(3): 512–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Bennani-Baiti IM, Machado I, Lombart-Bosch A, *et al.*: Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. *Hum Pathol*. 2012; 43(8): 1300–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Lv T, Yuan D, Miao X, *et al.*: Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. *PLoS One*. 2012; 7(4): e35065.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Kauffman EC, Robinson BD, Downes MJ, *et al.*: Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. *Mol Carcinog*. 2011; 50(12): 931–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 52. Huang Y, Greene E, Murray Stewart T, *et al.*: Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. *Proc Natl Acad Sci U S A*. 2007; 104(19): 8023–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Kahl P, Gullotti L, Heukamp LC, *et al.*: Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. *Cancer Res*. 2006; 66(23): 11341–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Harris WJ, Huang X, Lynch JT, *et al.*: The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. *Cancer Cell*. 2012; 21(4): 473–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. **F** Mould DP, McGonagle AE, Wiseman DH, *et al.*: Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date. *Med Res Rev*. 2015; 35(3): 586–618.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 56. Singh AB, Sharma A, Smith JJ, *et al.*: Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. *Gastroenterology*. 2011; 141(6): 2140–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 57. Jie D, Zhongmin Z, Guoqing L, *et al.*: Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer. *Dig Dis Sci*. 2013; 58(6): 1581–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Ding J, Zhang ZM, Xia Y, *et al.*: LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. *Br J Cancer*. 2013; 109(4): 994–1003.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. Bass AJ, Watanabe H, Mermel CH, *et al.*: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nat Genet*. 2009; 41(11): 1238–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 60. Hussenet T, Dali S, Exinger J, *et al.*: SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. *PLoS One*. 2010; 5(1): e8960.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Maier S, Wilbertz T, Braun M, *et al.*: SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. *Hum Pathol*. 2011; 42(8): 1078–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. **F** Zhang X, Lu F, Wang J, *et al.*: Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells. *Cell Rep*. 2013; 5(2): 445–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 63. Leis O, Egüara A, Lopez-Arribillaga E, *et al.*: Sox2 expression in breast tumours and activation in breast cancer stem cells. *Oncogene*. 2012; 31(11): 1354–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Cui X, Schiff R, Arpino G, *et al.*: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. *J Clin Oncol*. 2005; 23(30): 7721–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Huang Y, Vasilatos SN, Boric L, *et al.*: Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. *Breast Cancer Res Treat*. 2012; 131(3): 777–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 66. Huang J, Sengupta R, Espejo AB, *et al.*: p53 is regulated by the lysine demethylase LSD1. *Nature*. 2007; 449(7158): 105–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Lin T, Ponn A, Hu X, *et al.*: Requirement of the histone demethylase LSD1 in Snail-mediated transcriptional repression during epithelial-mesenchymal transition. *Oncogene*. 2010; 29(35): 4896–904.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 68. **F** Lin Y, Wu Y, Li J, *et al.*: The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. *EMBO J*. 2010; 29(11): 1803–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 69. Ambrosio S, Amente S, Saccà CD, *et al.*: LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene. *Oncotarget*. 2017; 8(3): 3854–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 70. **F** Ferrari-Amorotti G, Fragiasso V, Esteki R, *et al.*: Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. *Cancer Res*. 2013; 73(1): 235–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 71. **F** Carnesecchi J, Forcet C, Zhang L, *et al.*: ERR α induces H3K9 demethylation by LSD1 to promote cell invasion. *Proc Natl Acad Sci U S A*. 2017; 114(15): 3909–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 72. **F** Luo H, Shenoy AK, Li X, *et al.*: MOF Acetylates the Histone Demethylase LSD1 to Suppress Epithelial-to-Mesenchymal Transition. *Cell Rep*. 2016; 15(12): 2665–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 73. Wang Y, Zhang H, Chen Y, *et al.*: LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. *Cell*. 2009; 138(4): 660–72.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Philip Cole

Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, USA

Competing Interests: No competing interests were disclosed.

2. Barbara Majello

Department of Biology, University of Naples Federico II, Naples, Italy

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research